Total body irradiation-based versus busulfan-based myeloablative conditioning for single-unit cord blood transplantation in adults

References

• Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant. 1998;22(5):439–443.
   PubMed Web of Science ®Google Scholar
• Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98(13):3569–3574.
   PubMed Web of Science ®Google Scholar
• Kalaycio M, Bolwell B, Rybicki L, et al. BU- vs TBI-based conditioning for adult patients with ALL. Bone Marrow Transplant. 2011;46(11):1413–1417.
   PubMed Web of Science ®Google Scholar
• Cahu X, Labopin M, Giebel S, et al. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016;51(3):351–357.
   PubMed Web of Science ®Google Scholar
• Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–3878.
   PubMed Web of Science ®Google Scholar
• Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122(24):3863–3870.
   PubMed Web of Science ®Google Scholar
• Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen – a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2013;31(28):3549–3556.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104(12):3813–3820.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Ooi J, Tomonari A, et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood. 2007;109(3):1322–1330.
   PubMed Web of Science ®Google Scholar
• Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–660.
   PubMed Web of Science ®Google Scholar
• Terakura S, Atsuta Y, Tsukada N, et al. Comparison of outcomes of 8/8 and 7/8 Allele-Matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 2016;22(2):330–338.
   PubMed Web of Science ®Google Scholar
• Konuma T, Tsukada N, Kanda J, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 2016;91(5):E284–E292.
   PubMed Web of Science ®Google Scholar
• Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation Registry Retrospective Analysis. Lancet Haematol. 2019;6(11):e573–e584.
   PubMed Web of Science ®Google Scholar
• Miyao K, Terakura S, Kimura F, et al. Updated comparison of 7/8 HLA allele-matched unrelated bone marrow transplantation and single-unit umbilical cord blood transplantation as alternative donors in adults with acute leukemia. Biol Blood Marrow Transplant. 2020;26(11):2105–2114.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kanda J, Yamasaki S, et al. Single cord blood transplantation versus unmanipulated haploidentical transplantation for adults with acute myeloid leukemia in complete remission. Transplant Cell Ther. 2021;27(4):334.e1–334.e11.
   Google Scholar
• Barker JN, Kurtzberg J, Ballen K, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23(6):882–896.
   PubMed Web of Science ®Google Scholar
• Metheny L, Politikos I, Ballen KK, et al. Guidelines for adult patient selection and conditioning regimens in cord blood transplant recipients with hematologic malignancies and aplastic anemia. Transplant Cell Ther. 2021;27(4):286–291.
   PubMedGoogle Scholar
• Oran B, Wagner JE, DeFor TE, et al. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2011;17(9):1327–1334.
   PubMed Web of Science ®Google Scholar
• Baron F, Ruggeri A, Beohou E, et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016;7(28):43027–43038.
   PubMed Web of Science ®Google Scholar
• Sheth V, Volt F, Sanz J, et al. Reduced-intensity versus myeloablative conditioning in cord blood transplantation for acute myeloid leukemia (40–60 years) across highly mismatched HLA Barriers-on behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. Biol Blood Marrow Transplant. 2020;26(11):2098–2104.
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu X, Zheng C, et al. Retrospective cohort study comparing the outcomes of intravenous busulfan vs. total-body irradiation after single cord blood transplantation. Bone Marrow Transplant. 2019;54(10):1614–1624.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Oiwa-Monna M, et al. Cryopreserved CD34+ cell dose, but not total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft-versus-host disease after single-unit cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2017;23(7):1142–1150.
   PubMed Web of Science ®Google Scholar
• Mizusawa M, Konuma T, Kato S, et al. Clinical outcomes of persistent colonization with multidrug-resistant gram-negative rods in adult patients undergoing single cord blood transplantation. Int J Hematol. 2020;111(6):858–868.
   PubMed Web of Science ®Google Scholar
• Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–369.
   PubMed Web of Science ®Google Scholar
• Tomonari A, Takahashi S, Ooi J, et al. Cord blood transplantation for acute myelogenous leukemia using a conditioning regimen consisting of granulocyte colony-stimulating factor-combined high-dose cytarabine, fludarabine, and total body irradiation. Eur J Haematol. 2006;77(1):46–50.
   PubMed Web of Science ®Google Scholar
• Konuma T, Ooi J, Takahashi S, et al. Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT. Leuk Res. 2009;33(6):840–842.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Ooi J, et al. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. Biol Blood Marrow Transplant. 2014;20(3):396–401.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Oiwa-Monna M, et al. Single-unit cord blood transplant for acute lymphoblastic leukemia and lymphoma using an intensified conditioning regimen of total body irradiation, high-dose cytarabine and cyclophosphamide. Leuk Lymphoma. 2015;56(4):1148–1150.
   PubMed Web of Science ®Google Scholar
• Konuma T, Kato S, Isobe M, et al. Reduced-toxicity myeloablative conditioning consisting of fludarabine/busulfan/low-dose total body irradiation/granulocyte colony-stimulating factor-combined cytarabine in single cord blood transplantation for elderly patients with nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2019;25(4):764–770.
   PubMed Web of Science ®Google Scholar
• Konuma T, Monna-Oiwa M, Isobe M, et al. Radiation-free myeloablative conditioning consisting of fludarabine added to full-dose busulfan and cyclophosphamide in single-unit cord blood transplantation for adults. Eur J Haematol. 2021;107(3):374–376.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28(3):250–259.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Nakasone H, Fuji S, Yakushijin K, et al. Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. Am J Hematol. 2017;92(2):171–178.
   PubMed Web of Science ®Google Scholar
• Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31(6):701–709.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525–1536.
   PubMed Web of Science ®Google Scholar
• Horwitz ME, Morris A, Gasparetto C, et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant. 2008;14(5):591–594.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Di Stasi A, Andersson BS, et al. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014;14(1):e1–e5.
   PubMedGoogle Scholar
• Uchida N, Matsumoto K, Sakura T, et al. Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. Int J Hematol. 2020;112(4):510–523.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Uchida N, Yuasa M, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2016;22(10):1844–1850.
   PubMed Web of Science ®Google Scholar
• Konuma T, Ooi J, Uchida N, et al. Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica. 2014;99(12):e264–e268.
   PubMed Web of Science ®Google Scholar
• Konuma T, Takahashi S, Uchida N, et al. Effect of granulocyte colony-stimulating factor-combined conditioning in cord blood transplantation for myelodysplastic syndrome and secondary acute myeloid leukemia: a retrospective study in Japan. Biol Blood Marrow Transplant. 2015;21(9):1632–1640.
   PubMed Web of Science ®Google Scholar
• Arai Y, Takeda J, Aoki K, et al. Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood. 2015;126(3):415–422.
   PubMed Web of Science ®Google Scholar